

ZyVac TCV®: Questions and answers

What is ZyVac TCV?

ZyVac TCV is a World Health Organization (WHO)-prequalified typhoid conjugate vaccine (TCV) manufactured by Zydus Lifesciences Limited. It contains the Vi capsular polysaccharide of *Salmonella* Typhi conjugated to tetanus toxoid.

Who can receive ZyVac TCV?

ZyVac TCV can be administered to individuals aged 6 months to 65 years.

What is the dosage schedule for ZyVac TCV?

ZyVac TCV is administered as a single 0.5 mL intramuscular dose for individuals aged 6 months and older. In countries with a high burden of typhoid or high rates of drug-resistant typhoid, WHO recommends a booster dose, particularly for children who received a first dose younger than 2 years of age.

Is ZyVac TCV safe?

WHO has reviewed clinical data and determined that ZyVac TCV is safe and well-tolerated.

Is ZyVac TCV effective?

Clinical trials have demonstrated strong immunogenicity across age groups, with safety and immune response profiles comparable to Typbar TCV.

Can ZyVac TCV be given at the same time as other childhood vaccines?

ZyVac TCV can be co-administered with other routine vaccines, including yellow fever, measles-rubella, meningococcal conjugate vaccines, polio, human papillomavirus (HPV), and malaria vaccines.

Is ZyVac TCV prequalified by WHO?

WHO prequalified ZyVac TCV in October 2024, indicating it meets international standards for quality, safety, and efficacy and is eligible for procurement by United Nations agencies. It is an important step for inclusion in Gavi, the Vaccine Alliance's investment strategy, which helps finance vaccine access in Gavi-eligible countries.



Photo: Biospectrum India.

Does Gavi support the introduction of ZyVac TCV?

ZyVac TCV is available with Gavi support for introduction in eligible countries.

Which countries are using ZyVac TCV?

As of April 2026, no countries have introduced ZyVac TCV, though it is considered interchangeable with other WHO-prequalified TCVs.

TYPHOID CONJUGATE VACCINES

What are TCVs?

TCVs are made by linking the Vi capsular polysaccharide of the typhoid bacteria to a more complex protein. Through conjugation, TCVs stimulate parts of the immune system that older typhoid vaccines cannot, thereby inducing a stronger, longer-lasting immunity among a broader age range.

What are the benefits of TCVs?

TCVs are proven to offer protection for at least four years with a single dose and are suitable for children 6 months of age and older, allowing delivery through routine childhood immunization programs. Expanded use of TCVs through routine immunization has the potential to reduce the need for antibiotics, slow further emergence of drug-resistant typhoid strains, and save lives. TCVs are projected to be one of the most impactful vaccines for preventing drug-resistance-associated deaths.

Learn more and join the effort at www.takeontyphoid.org.

#TakeOnTyphoid